Newron Pharmaceuticals SpA has secured $45.0 million in new investment capital from investors. The biopharmaceutical company is dedicated to the development of novel therapies for patients suffering from diseases of the central nervous system (CNS) and pain. Headquartered in Bresso, Italy, with a subsidiary in Morristown, NJ, USA, Newron focuses on delivering innovative treatments to improve the quality of life for patients with CNS disorders.
The company has built a balanced and robust pipeline of drug candidates at various clinical stages. Newron also has a proven track record of drug development and commercialization, notably with Xadago® (safinamide). Xadago® has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, and the U.S., and is commercialized globally through a network of partners including Zambon, Supernus Pharmaceuticals, and Meiji Seika.
This $45.0 million funding round is a significant step for Newron, providing substantial capital to accelerate its strategic growth initiatives. The funds are expected to be deployed to advance the company’s promising pipeline, which includes Evenamide, a potential first add-on therapy for schizophrenia, and ralfinamide, targeting specific rare pain indications. This investment will support ongoing clinical development programs and strengthen the company’s operational capabilities.
Newron Pharmaceuticals SpA is listed on the SIX Swiss Exchange and remains committed to its mission of addressing unmet medical needs. The company plans to leverage this capital to further its research and development efforts, aiming to bring innovative treatments to patients worldwide and expand its impact in the biopharmaceutical sector.
